Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2003
IR News
2003 IR News
RSS
IR News
12.22.2003
Santen Reorganizes Domestic Sales Operation [PDF:14KB]
12.18.2003
Santen Signs Agreement With Johnson & Johnson Vision Care, Inc. To Supply Prescription Ophthalmic Products [PDF:18KB]
11.05.2003
Santen Announces Financial Results for the First Six Months ended September 30, 2003 [PDF:15KB]
09.05.2003
Santen Announces Closure of its U.S. Subsidiary, Phacor Inc. [PDF:15KB]
08.11.2003
Santen Files for Manufacturing Approval for its Vernal Keratoconjunctivitis Treatment, Ciclosporin Ophthalmic Solution [PDF:19KB]
07.31.2003
Santen Announces Financial Results for the First Quarter of Fiscal Year 2003 (Three Months Ended June 30, 2003)
06.26.2003
Santen Hosts the 91st Annual General Meeting of Shareholders
06.05.2003
Notice of the 91st Annual General Meeting of Shareholders [PDF:60KB]
05.09.2003
Santen Announces Proposed Change of Accounting Auditors [PDF:15KB]
05.09.2003
Santen Announces Financial Results for the Year ended March 31, 2003 [PDF:57KB]
05.09.2003
Santen to Issue Stock Acquisition Rights for the Purpose of Granting Stock Options [PDF:22KB]
05.09.2003
Santen to Shorten Office Term of Directors and Appoint Outside Director [PDF:14KB]
05.09.2003
Notice Regarding Share Buyback [PDF:14KB]
05.06.2003
Santen Submits New Drug Application to FDA for Levofloxacin 1.5% Ophthalmic Solution [PDF:15KB]
03.04.2003
Santen Purchases Own Shares on Market by ToSTNet-2 [PDF:12KB]
03.03.2003
Santen to Purchase Own Shares on Market by ToSTNet-2 [PDF:15KB]
02.20.2003
Revision of Performance Forecasts[PDF:41KB]
02.20.2003
2003-2005 Medium-term Management Plan [PDF:38KB]
News Archive
